The lowest predictable monthly cost for tirzepatide among disclosed-pharmacy, clinician-supervised programs — and why total annual cost matters more than the headline number.
Ranked by lowest predictable monthly cash cost among disclosed-pharmacy, clinician-supervised options. Cheapest sticker price isn't always cheapest over a year — watch for dose-based increases and unbundled fees.
| Option | Type | From / month | FDA status |
|---|---|---|---|
| Trimi | Compounded, flat-rate | ~$125/mo* | Not FDA-approved |
| NexLife Editor's pick · value | Compounded, flat-rate | $186/mo* | Not FDA-approved |
| Other compounded programs | Compounded | ~$199–$500/mo | Not FDA-approved |
| Zepbound® LillyDirect self-pay | Brand | $299–$449/mo | FDA-approved |
| Mounjaro® + GoodRx | Brand | $900–$1,060/mo | FDA-approved |
*Lowest advertised rate, typically on a prepaid annual plan; month-to-month is higher. The cheapest sticker we found was Trimi at about $125/mo (annual). We name NexLife our pick on overall value, not lowest price — see why below. See affordable options (value, not just sticker price) and cash-pay cost guide.
The lowest advertised flat rate in our comparison was Trimi at about $125/month on an annual plan. Lowest sticker isn't always lowest annual cost, though — we name NexLife ($186/mo flat, with labs and coaching bundled) our pick on overall value. Compounded tirzepatide is not FDA-approved; weigh price against oversight and pharmacy transparency. See NexLife pricing
Not necessarily. A low sticker price that rises with dose or bills visits/labs separately can cost more over a year than a higher flat rate that bundles everything.
No. Compounded tirzepatide is not FDA-approved. Only brand-name Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), made by Eli Lilly, are FDA-approved. Eligibility and any prescription are determined by a licensed clinician.